QCG
ONC

Quadrant Capital Group’s BeOne Medicines Ltd ONC Stock Holding History

Quadrant Capital Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
4,647
+1,974
+74% +$582K 0.04% 466
2026
Q1 		$794K Buy
2,673
+27
+1% +$8.74K 0.02% 668
2025
Q4 		$804K Buy
2,646
+22
+0.8% +$7.2K 0.02% 660
2025
Q3 		$894K Buy
2,624
+20
+0.8% +$6.07K 0.03% 566
2025
Q2 		$630K Buy
2,604
+2,377
+1,047% +$583K 0.02% 730
2025
Q1 		$61.8K Buy
227
+18
+9% +$4.21K ﹤0.01% 1649
2024
Q4 		$38.6K Buy
209
+67
+47% +$13.7K ﹤0.01% 1560
2024
Q3 		$31.9K Buy
142
+79
+125% +$14.2K ﹤0.01% 1696
2024
Q2 		$8.99K Sell
63
-23
-27% -$3.54K ﹤0.01% 2153
2024
Q1 		$13.4K Sell
86
-28
-25% -$4.51K ﹤0.01% 1996
2023
Q4 		$20.6K Sell
114
-1
-0.9% -$181 ﹤0.01% 1812
2023
Q3 		$20.7K Buy
115
+3
+3% +$594 ﹤0.01% 1696
2023
Q2 		$20K Sell
112
-2
-2% -$461 ﹤0.01% 1716
2023
Q1 		$24.6K Buy
114
+4
+4% +$959 ﹤0.01% 1586
2022
Q4 		$24.2K Buy
110
+63
+134% +$11.6K ﹤0.01% 1569
2022
Q3 		$6K Buy
47
+26
+124% +$4.46K ﹤0.01% 2107
2022
Q2 		$3K Sell
21
-16
-43% -$2.5K ﹤0.01% 2160
2022
Q1 		$7K Sell
37
-258
-87% -$54.8K ﹤0.01% 1818
2021
Q4 		$80K Sell
295
-19
-6% -$6.42K 0.01% 749
2021
Q3 		$114K Buy
314
+88
+39% +$28.8K 0.02% 573
2021
Q2 		$78K Buy
226
+41
+22% +$13.6K 0.01% 692
2021
Q1 		$64K Sell
185
-55
-23% -$18.2K 0.01% 727
2020
Q4 		$62K Sell
240
-68
-22% -$18.7K 0.01% 685
2020
Q3 		$88K Buy
308
+136
+79% +$32K 0.02% 466
2020
Q2 		$32K Sell
172
-952
-85% -$155K 0.01% 892
2020
Q1 		$139K Buy
1,124
+961
+590% +$150K 0.02% 471
2019
Q4 		$25K Sell
163
-185
-53% -$30.7K ﹤0.01% 1643
2019
Q3 		$42K Sell
348
-147
-30% -$19.5K 0.01% 1297
2019
Q2 		$60K Buy
495
+131
+36% +$16.6K 0.01% 1136
2019
Q1 		$47K Buy
364
+207
+132% +$27.9K 0.01% 1263
2018
Q4 		$22K Buy
+157
New +$20.8K 0.01% 1156

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrant Capital Group's ONC Position: Q2 2026 in Review

Quadrant Capital Group increased its BeOne Medicines Ltd (ONC) stake by 74% in Q2 2026, buying an estimated $582K and bringing the position to 4,647 shares worth $1.32M. The position accounts for 0.04% of the portfolio, ranked #466.

Quadrant Capital Group first reported a position in ONC in Q4 2018 and has held it in 31 quarters since. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Quadrant Capital Group held 4,647 shares of BeOne Medicines Ltd worth $1.32M as of Q2 2026.
  • Quadrant Capital Group bought 1,974 BeOne Medicines Ltd shares in Q2 2026, an estimated $582K.
  • BeOne Medicines Ltd made up 0.04% of Quadrant Capital Group's portfolio in Q2 2026, its #466 holding.
  • Quadrant Capital Group first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 31 quarters since.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.